GRI

GLP-1 agonist drugs may only be sold with prescription retention

News Healthcare & Pharma Law & Policy Updates
Date: 16th Apr, 2025 Source: National Health Surveillance Agency (Anvisa) Country: Brazil Original Source

Brief

On 16/04/2024, the "National Health Surveillance Agency (Anvisa)" issued an update regarding "GLP-1 agonist drugs may only be sold with prescription retention". The agency approved a stricter control on prescription and dispensation of these medications, which include semaglutide, liraglutide, dulaglutide, exenatida, tirzepatide, and lixisenatide.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
SNVS: Published a new version of the Guide for Quality Management System Implementation
Date: 23rd Apr, 2025 Source: National Health Surveillance Agency (Anvisa) Country: Brazil
News Healthcare & Pharma Guidance
Further emergency registrations against the reed glass wing zikade
Date: 23rd Apr, 2025 Source: Federal Office of Consumer Protection and Food Safety Country: Germany
News Environment Law & Policy Updates
Cabinet Decision on “Cabinet Order to Determine the Effective Date of the Act Partially Amending the Act on Promoting the Supply of Rental Housing for Persons with Special Needs in Securing Housing”
Date: 22nd Apr, 2025 Source: Ministry of Land, Infrastructure, Transport and Tourism (MLIT) Country: Japan
News Real Estate & Property Law & Policy Updates

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales